Healthcare / Medical DevicesNYSE
$24.80
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF n/d · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-9.4%
↓Gross Margin
50.5%
↑Debt/Equity
0.12
↓Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
-6.5%
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue $701.2M · net income $-72.9M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | $701.2M | $701.2M | $687.8M | $673.3M | $684.1M | $587.0M | $714.8M | $697.6M | $652.3M | $611.6M | $566.2M | $509.0M | $1.67B | $1.68B | $1.68B |
| Net Income | $-72.9M | $-72.9M | $-392.1M | $-61.8M | $50.5M | $6.3M | $-29.0M | $-45.9M | $57.5M | $79.3M | $39.8M | $-426.3M | $27.1M | $154.6M | $152.6M |
| EBITDA | $-22.7M | $-22.7M | $-350.7M | $50.3M | $83.2M | $-700000.00 | $-5.6M | $-18.8M | $34.0M | $16.4M | $-41.9M | $-70.3M | $179.7M | $294.5M | $285.6M |
| EPS | -1.57 | -1.57 | -8.53 | -1.32 | 1.07 | 0.13 | -0.61 | -0.96 | 1.22 | 1.69 | 0.85 | -9.15 | 0.58 | 3.32 | 3.28 |
| Gross Margin | 50.5% | 50.5% | 55.4% | 56.4% | 57.6% | 51.0% | 51.9% | 57.7% | 59.9% | 55.1% | 52.5% | 50.6% | 32.8% | 36.5% | 35.8% |
| Operating Margin | -8.8% | -8.8% | -57.6% | 0.6% | 5.2% | -6.6% | -6.8% | -8.0% | 0.1% | -7.0% | -18.9% | -26.7% | 5.6% | 13.4% | 13.5% |
| Net Margin | -10.4% | -10.4% | -57.0% | -9.2% | 7.4% | 1.1% | -4.1% | -6.6% | 8.8% | 13.0% | 7.0% | -83.8% | 1.6% | 9.2% | 9.1% |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 0.12 | 0.12 | 0.15 | 0.13 | 0.18 | 0.10 | 0.14 | 0.19 | 0.19 | 0.45 | 0.53 | 0.55 | 0.42 | 0.00 | — |
| Returns | |||||||||||||||
| ROE | -9.4% | -9.4% | -47.3% | -5.0% | 3.9% | 0.5% | -2.3% | -3.6% | 4.4% | 6.5% | 3.6% | -40.4% | 1.8% | 7.4% | 7.4% |
| Growth & Yield | |||||||||||||||
| Revenue Growth | 1.9% | 1.9% | 2.2% | -1.6% | 16.5% | -17.9% | 2.5% | 6.9% | 6.7% | 8.0% | 11.2% | -69.6% | -0.3% | -0.4% | — |
| EPS Growth | 81.6% | 81.6% | -546.2% | -223.4% | 723.1% | 121.3% | 36.5% | -178.7% | -27.8% | 98.8% | 109.3% | -1677.6% | -82.5% | 1.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.